<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651675</url>
  </required_header>
  <id_info>
    <org_study_id>FHGT002</org_study_id>
    <secondary_id>P01HL059407</secondary_id>
    <nct_id>NCT02651675</nct_id>
  </id_info>
  <brief_title>A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)</brief_title>
  <official_title>AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study is intended to evaluate the safety and preliminary effectiveness of
      AAV-based liver-directed gene therapy in the treatment of adults with Homozygous Familial
      Hypercholesterolemia (HoFH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic metabolic disorder
      characterized by absent or severely reduced capacity to catabolize circulating LDL particles
      by the hepatic LDL receptor. As a consequence, HoFH subjects present abnormal total plasma
      cholesterol (LDL-C) levels, resulting in severe atherosclerosis often leading to early onset
      of cardiovascular disease. Early initiation of aggressive treatment for these patients is
      therefore essential. Unfortunately, despite existing therapies, treated LDL-C levels could
      remain well above acceptable levels. Thus, the functional replacement of the defective LDLR
      via AAV-based liver-directed gene therapy may be a viable approach to treat this disease and
      improve response to current lipid-lowering treatments. This first-in-human study is intended
      to evaluate the safety of this gene therapy investigational product and assess preliminary
      evidence of efficacy using plasma LDL-C levels as a surrogate biomarker for human LDLR
      transgene expression. Subjects may be asked to participate in an optional kinetics study to
      assess the metabolic mechanism by which LDL-C is reduced.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing investigational product-related adverse events</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Physical examinations; Clinical laboratory parameters; and adverse event reporting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in in LDL-C</measure>
    <time_frame>18 weeks, 12 weeks for cohort 1 only, compared to baseline.</time_frame>
    <description>Percent change in LDL-C compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lipid parameters compared to baseline values</measure>
    <time_frame>18 weeks, 12 weeks for cohort 1 only, compared to baseline.</time_frame>
    <description>total cholesterol (TC); non-high density lipoprotein cholesterol (non-HDL-C); HDL-C; fasting triglycerides (TG); overflow density lipoprotein cholesterol (VLDL-C); lipoprotein(a) (Lp(a)); apolipoprotein B (apoB) and apolipoprotein A-I (apo A-I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing investigational product-related adverse events</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>Physical examinations; Clinical laboratory parameters; and adverse event reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of vector shedding</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>Amount of virus secreted in urine and plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia (HoFH)</condition>
  <arm_group>
    <arm_group_label>AAV directed hLDLR gene therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV directed hLDLR gene therapy</intervention_name>
    <description>A novel adeno-associated viral (AAV) vector with human low-density lipoprotein receptor (hLDLR) gene</description>
    <arm_group_label>AAV directed hLDLR gene therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years of age.

          -  Untreated and/or treated LDL-C levels and clinical presentation consistent with the
             diagnosis of homozygous FH

          -  Molecularly defined LDLR mutations at both LDLR alleles.

          -  A baseline serum AAV8 NAb titer ≤ 1:10.

        Exclusion Criteria

          -  Unwilling to wash out of the following lipid lowering therapies for the pre-specified
             time period:

               1. niacin &gt; 250 mg/day: within 6 weeks of baseline

               2. fibrates: within 4 weeks of baseline

               3. lomitapide: within 8 weeks of baseline

               4. mipomersen: within 24 weeks of baseline

          -  History of cirrhosis or chronic liver disease based on documented histological
             evaluation or non-invasive imaging or testing.

          -  Abnormal liver function tests (LFTs) at screening (AST or ALT &gt; 2 × upper limit of
             normal (ULN) and/or Total Bilirubin of &gt; 1.5 × ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boca Raton location</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Location</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland location</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Location</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville location</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicoutimi location</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal location</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal location</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palermo location</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rome location</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotterdam location</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL Receptors</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Rare diseases</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

